Loading...

COYA COYA THERAPEUTICS INC Capital Structure Changes 8-K Filing

CY T

CY

COYA THERAPEUTICS INC

(COYA)

2026 8-K

Sales Agreement Details

FDA Fast Track Designation

Director Resignation

Operational Results Report

Stock Offering Announcement

Financial Update

Positive Study Results

Milestone Payment Received

Financial Update

Stock Offering Launch

Milestone Payment

Clinical Trials

Clinical Trials

Earnings Releases

Financial Results

Quarterly Results

Director Resignation

Management Changes

Clinical Trial Results

Management Change

Quarterly Results

Other Special Situation

Agreement Amendment

Securities Purchase Agreement

Earnings Reports

Results of Operations and F...

Quantitative Data

Development and License Agr...

Results of Operations and F...

Earnings Report

Quantitative Data

Quantitative Data

Quantitative Data

Quantitative Data

Earnings Reports

Earnings Reports

License Agreement with Dr. ...

Conference Call for ALS Cli...

Banking Relationship

Equity Compensation Grants

External Links:

Coya Therapeutics, Inc. reported a cash balance of $46.8 million as of December 31, 2025, indicating a cash runway extending into the second half of 2027, and expects topline data from its ALSTARS Phase 2 trial in Q1 2027.

AI Assistant

COYA THERAPEUTICS INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.